FRET based ratio-metric sensing of hyaluronidase in synthetic urine as a biomarker for bladder and prostate cancer

Rahul Chib, Sangram Limbaji Raut, Rafal Fudala, Aaron Chang, Mark Mummert, Ryan Rich, Zygmunt Gryczynski, Ignacy Gryczynski

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Elevated hyaluronidase levels are found in the urine of bladder and prostate cancer patients. Therefore, HA-ase is regarded as an important biomarker for the detection of these cancers. In this report, we use a FRET based ratiometric sensing approach to detect the level of HA-ase in synthetic urine. For this, we have used a HA-FRET probe (hyaluronan) labeled with fluorescein as a donor and rhodamine as an acceptor. We monitor the digestion of our HA-FRET probe with different concentrations of HA-ase in synthetic urine via fluorescence emission. The extent to which FRET is released depends on the concentration of HA-ase. Our fluorescence intensity results are also supported with time resolved fluorescence decay data. This assay can be used to develop a non-invasive technique for the detection of bladder and/or prostate cancer progression.

Original languageEnglish
Pages (from-to)470-474
Number of pages5
JournalCurrent Pharmaceutical Biotechnology
Volume14
Issue number4
DOIs
StatePublished - 14 Jun 2013

Fingerprint

Hyaluronoglucosaminidase
Urinary Bladder Neoplasms
Prostatic Neoplasms
Biomarkers
Fluorescence
Urine
Rhodamines
Hyaluronic Acid
Tumor Biomarkers
Fluorescein
Digestion
Tissue Donors

Keywords

  • Bladder cancer
  • HA-FRET
  • Hyaluronidase
  • Ratiometric sensing

Cite this

@article{e5d97980c04544f1aa23731db76d292f,
title = "FRET based ratio-metric sensing of hyaluronidase in synthetic urine as a biomarker for bladder and prostate cancer",
abstract = "Elevated hyaluronidase levels are found in the urine of bladder and prostate cancer patients. Therefore, HA-ase is regarded as an important biomarker for the detection of these cancers. In this report, we use a FRET based ratiometric sensing approach to detect the level of HA-ase in synthetic urine. For this, we have used a HA-FRET probe (hyaluronan) labeled with fluorescein as a donor and rhodamine as an acceptor. We monitor the digestion of our HA-FRET probe with different concentrations of HA-ase in synthetic urine via fluorescence emission. The extent to which FRET is released depends on the concentration of HA-ase. Our fluorescence intensity results are also supported with time resolved fluorescence decay data. This assay can be used to develop a non-invasive technique for the detection of bladder and/or prostate cancer progression.",
keywords = "Bladder cancer, HA-FRET, Hyaluronidase, Ratiometric sensing",
author = "Rahul Chib and Raut, {Sangram Limbaji} and Rafal Fudala and Aaron Chang and Mark Mummert and Ryan Rich and Zygmunt Gryczynski and Ignacy Gryczynski",
year = "2013",
month = "6",
day = "14",
doi = "10.2174/13892010113149990222",
language = "English",
volume = "14",
pages = "470--474",
journal = "Current Pharmaceutical Biotechnology",
issn = "1389-2010",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

FRET based ratio-metric sensing of hyaluronidase in synthetic urine as a biomarker for bladder and prostate cancer. / Chib, Rahul; Raut, Sangram Limbaji; Fudala, Rafal; Chang, Aaron; Mummert, Mark; Rich, Ryan; Gryczynski, Zygmunt; Gryczynski, Ignacy.

In: Current Pharmaceutical Biotechnology, Vol. 14, No. 4, 14.06.2013, p. 470-474.

Research output: Contribution to journalArticle

TY - JOUR

T1 - FRET based ratio-metric sensing of hyaluronidase in synthetic urine as a biomarker for bladder and prostate cancer

AU - Chib, Rahul

AU - Raut, Sangram Limbaji

AU - Fudala, Rafal

AU - Chang, Aaron

AU - Mummert, Mark

AU - Rich, Ryan

AU - Gryczynski, Zygmunt

AU - Gryczynski, Ignacy

PY - 2013/6/14

Y1 - 2013/6/14

N2 - Elevated hyaluronidase levels are found in the urine of bladder and prostate cancer patients. Therefore, HA-ase is regarded as an important biomarker for the detection of these cancers. In this report, we use a FRET based ratiometric sensing approach to detect the level of HA-ase in synthetic urine. For this, we have used a HA-FRET probe (hyaluronan) labeled with fluorescein as a donor and rhodamine as an acceptor. We monitor the digestion of our HA-FRET probe with different concentrations of HA-ase in synthetic urine via fluorescence emission. The extent to which FRET is released depends on the concentration of HA-ase. Our fluorescence intensity results are also supported with time resolved fluorescence decay data. This assay can be used to develop a non-invasive technique for the detection of bladder and/or prostate cancer progression.

AB - Elevated hyaluronidase levels are found in the urine of bladder and prostate cancer patients. Therefore, HA-ase is regarded as an important biomarker for the detection of these cancers. In this report, we use a FRET based ratiometric sensing approach to detect the level of HA-ase in synthetic urine. For this, we have used a HA-FRET probe (hyaluronan) labeled with fluorescein as a donor and rhodamine as an acceptor. We monitor the digestion of our HA-FRET probe with different concentrations of HA-ase in synthetic urine via fluorescence emission. The extent to which FRET is released depends on the concentration of HA-ase. Our fluorescence intensity results are also supported with time resolved fluorescence decay data. This assay can be used to develop a non-invasive technique for the detection of bladder and/or prostate cancer progression.

KW - Bladder cancer

KW - HA-FRET

KW - Hyaluronidase

KW - Ratiometric sensing

UR - http://www.scopus.com/inward/record.url?scp=84878786852&partnerID=8YFLogxK

U2 - 10.2174/13892010113149990222

DO - 10.2174/13892010113149990222

M3 - Article

C2 - 23360262

AN - SCOPUS:84878786852

VL - 14

SP - 470

EP - 474

JO - Current Pharmaceutical Biotechnology

JF - Current Pharmaceutical Biotechnology

SN - 1389-2010

IS - 4

ER -